Catherine Clark

Could an Eczema Drug Revolutionise Depression Treatment?

 Researchers are exploring a groundbreaking link between the immune system and mental health that could fundamentally change how we treat psychiatric disorders. A collaborative study between a psychiatrist and a dermatologist at Mount Sinai has uncovered that some forms of depression share a specific immune "signature" with inflammatory skin conditions like eczema.

The Science: The "Type 2" Pathway

The study focused on the type 2 immune pathway, which involves T helper 2 (Th2) cells. While this pathway is designed to fight off parasites, it can become hyperactive in conditions like asthma, allergies, and atopic dermatitis (eczema). Researchers discovered that this same pathway is ramped up in people with depression, and its activity levels often correlate with the severity of the patient's symptoms.

Using computer modelling and animal testing, the team found that dupilumab, an antibody currently used to treat eczema, successfully resolved depression-like symptoms in mice. Rather than suppressing the immune system, this treatment acts as an "immune correction," bringing the overactive pathway back into a normal range.

How Inflammation Affects the Brain

The link between the immune system and mood is rooted in how inflammation impacts brain function:

1. Suppressed Reward System: High levels of inflammatory markers in the blood are linked to a blunted response in the brain’s reward centre (the nucleus accumbens), leading to symptoms like a lack of motivation and pleasure.
2. Heightened Threat Response: Conversely, inflammation makes the amygdala, the brain region attuned to threats, hyperreactive to negative stimuli, such as sad or fearful faces.

The Future: Personalised "Immune Psychiatry"

The researchers are now launching a clinical trial to test dupilumab in humans with treatment-resistant depression. This research points towards a future where individuals are offered more targeted psychiatric treatment options. 

Instead of a broad diagnosis, patients might one day receive a blood test to identify a specific "immune subtype" of depression. Thus supporting the application of targeted immune therapies based on a patient's unique biological markers, potentially providing relief for those who haven't responded to traditional antidepressants

This is truly exciting research, and I look forward to seeing how this field evolves as researchers continue to define these specific immune pathways and move toward personalised treatments in the coming years.

Reference:

He, H., Cathomas, F., Parise, L. F., David, E., Rizk, M., Hawkins, K., Karpman, E., Russo, S. J., Guttman, E., & Murrough, J. W. (2026). Major depressive disorder shares systemic immune signatures and potential therapeutic targets with inflammatory skin diseases. Molecular psychiatry, 10.1038/s41380-025-03383-5. Advance online publication. https://doi.org/10.1038/s41380-025-03383-5